{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T14:15:12Z","timestamp":1792937712342,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["xzy012020061"],"award-info":[{"award-number":["xzy012020061"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003047"],"award-info":[{"award-number":["82003047"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174164"],"award-info":[{"award-number":["82174164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002412","name":"Xi\u2019an Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.breast.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T06:32:04Z","timestamp":1682058724000},"page":"392-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score"],"prefix":"10.1016","volume":"69","author":[{"given":"Cong","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingcong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-7849","authenticated-orcid":false,"given":"Shuqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2023.04.002_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib2","first-page":"1","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J Nat Canc Center"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib3","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41467-018-05228-y","article-title":"The therapeutic significance of mutational signatures from DNA repair deficiency in cancer","volume":"9","author":"Ma","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.breast.2023.04.002_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.breast.2023.04.002_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib7","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.breast.2023.04.002_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/em.22505","article-title":"A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies","volume":"63","author":"Shao","year":"2022","journal-title":"Environ Mol Mutagen"},{"issue":"12","key":"10.1016\/j.breast.2023.04.002_bib9","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1002\/ijc.32918","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients","volume":"146","author":"Su","year":"2020","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.breast.2023.04.002_bib10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2023.04.002_bib11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrd3374","article-title":"Harnessing synthetic lethal interactions in anticancer drug discovery","volume":"10","author":"Chan","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.breast.2023.04.002_bib12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.breast.2023.04.002_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2022.12.031","article-title":"Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control","author":"Concannon","year":"2023","journal-title":"Mol Cell"},{"issue":"6","key":"10.1016\/j.breast.2023.04.002_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41568-019-0145-5","article-title":"Going to extremes: determinants of extraordinary response and survival in patients with cancer","volume":"19","author":"Saner","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.breast.2023.04.002_bib15","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s11912-022-01337-6","article-title":"Resistance to poly (ADP-Ribose) polymerase inhibitors (PARPi): mechanisms and potential to reverse","volume":"24","author":"Washington","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.breast.2023.04.002_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2023.04.002_bib17","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.breast.2023.04.002_bib18","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.7150\/thno.36281","article-title":"A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.breast.2023.04.002_bib19","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1158\/1078-0432.CCR-15-2137","article-title":"Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and\/or BRCA mutation-associated breast cancer","volume":"22","author":"Rodler","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.breast.2023.04.002_bib20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2020.38.15_suppl.1001","article-title":"Results of a phase II randomized trial of cisplatin +\/- veliparib in metastatic triple-negative breast cancer (TNBC) and\/or germline BRCA-associated breast cancer (SWOG S1416)","volume":"38","author":"Sharma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2023.04.002_bib21","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.breast.2023.04.002_bib22","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2023.04.002_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1101\/gr.241414.118","article-title":"Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes","volume":"29","author":"Sherill-Rofe","year":"2019","journal-title":"Genome Res"},{"issue":"5","key":"10.1016\/j.breast.2023.04.002_bib24","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/bcr3049","article-title":"Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness","volume":"13","author":"Lips","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"7793","key":"10.1016\/j.breast.2023.04.002_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.breast.2023.04.002_bib26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.breast.2023.04.002_bib27","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2023.04.002_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118434","article-title":"Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy","volume":"261","author":"Gou","year":"2020","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.breast.2023.04.002_bib29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","article-title":"Association of BRCA1\/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","volume":"16","author":"Timms","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2023.04.002_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-018-0066-6","article-title":"Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer","volume":"4","author":"Sztupinszki","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.breast.2023.04.002_bib31","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Panel m: Personalizing the treatment of women with early breast cancer: highlights of the St gallen international Expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2023.04.002_bib32","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/annonc\/mdq612","article-title":"HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer","volume":"22","author":"Yao","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.breast.2023.04.002_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/1471-0528.17324","article-title":"Genomic Scar Score: a robust model predicting homologous recombination deficiency based on genomic instability","volume":"129","author":"Yuan","year":"2022","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and College of American pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib35","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.breast.2023.04.002_bib36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","article-title":"Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)","volume":"151","author":"Kaklamani","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.breast.2023.04.002_bib37","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","article-title":"Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105","volume":"33","author":"Telli","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.breast.2023.04.002_bib38","first-page":"A366","article-title":"216 an evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer","volume":"31","author":"Weichert","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"10.1016\/j.breast.2023.04.002_bib39","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-16-3227","article-title":"Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients","volume":"23","author":"Sun","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","article-title":"Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","volume":"22","author":"O'Shaughnessy","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2023.04.002_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"issue":"3","key":"10.1016\/j.breast.2023.04.002_bib42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-018-05120-9","article-title":"Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC","volume":"174","author":"Imanishi","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13402-013-0158-0","article-title":"Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications","volume":"37","author":"Yiannakopoulou","year":"2014","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41523-021-00315-8","article-title":"Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families","volume":"7","author":"Matis","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.breast.2023.04.002_bib45","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.breast.2023.04.002_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2023.04.002_bib47","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/jnci\/djaa175","article-title":"Molecular features and functional implications of germline variants in triple-negative breast cancer","volume":"113","author":"Ma","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2023.04.002_bib48","article-title":"Survival outcomes in women with unilateral, triple-negative, breast cancer correlated with contralateral prophylactic mastectomy","author":"Fasano","year":"2023","journal-title":"Ann Surg Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762300437X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762300437X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:48:25Z","timestamp":1760777305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762300437X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":48,"alternative-id":["S096097762300437X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.04.002","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}